Investigational drug · Phase 3
OLZ
Also called: SAM, ALKS 3831
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bipolar I Disorder, Schizophrenia.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
11
Any phase or sponsor naming "OLZ"
First trial start
2021
Oct 22, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OLZ", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bipolar I Disorder
- Schizophrenia
Approved drugs for the same conditions: Schizophrenia · Bipolar disorder · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "OLZ" as an intervention, largest first.
- Lurasidone HCl A Phase 3 Study of Patients With Acute SchizophreniaPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00615433 · 478 participants · Start Jan 2008 · Primary completion Dec 2009
Drug: Lurasidone; Olanzapine and 2 more · For: Schizophrenia
Sites: Little Rock, Arkansas; Cerritos, California; Oceanside, California · 52 sites in all
- Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsPivotal-lookingEnrolling by invitation
Alkermes, Inc.Industry
NCT04987229 · 236 participants (planned) · Start Oct 22, 2021 · Primary completion Sep 2027
Drug: OLZ/SAM · For: Bipolar I Disorder; Schizophrenia
Sites: Dothan, Alabama; Little Rock, Arkansas; Stanford, California · 35 sites in all
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT05303064 · 220 participants (planned) · Start Jun 30, 2022 · Primary completion Sep 2026
Drug: OLZ/SAM; Olanzapine · For: Schizophrenia; Bipolar I Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; Encino, California · 47 sites in all
- Olanzapine Anorexia CachexiaPivotal-lookingCompleted
Cairo UniversityAcademic, hospital or other
NCT05243251 · 164 participants · Start Dec 25, 2021 · Primary completion Nov 21, 2022
Drug: Olanzapine 5 MG; Placebo · For: Anorexia
Sites: Cairo, Egypt
University of Sao PauloAcademic, hospital or other
NCT07190482 · 50 participants · Start Oct 1, 2023 · Primary completion Dec 20, 2024
Drug: Olanzapine 5 Mg ORAL TABLET; Placebo Drug · For: Tinnitus; Tinnitus, Subjective
Sites: São Paulo, Brazil
Impel PharmaceuticalsIndustry
NCT03624322 · 38 participants · Start Aug 5, 2018 · Primary completion Oct 3, 2018
Drug: Zyprexa IM; Zydis and 1 more · For: Acute Agitation
Sites: Melbourne, Australia
Alkermes, Inc.Industry
NCT05547100 · 12 participants · Start Sep 14, 2022 · Primary completion Nov 19, 2022
Drug: LYBALVI · For: Focus of Study is on Healthy Lactating Women
Sites: Las Vegas, Nevada
Alkermes, Inc.Industry
NCT04987658 · 7 participants · Start Jul 22, 2021 · Primary completion Aug 11, 2023
Drug: OLZ/SAM · For: Bipolar I Disorder
Sites: Decatur, Georgia; Cincinnati, Ohio
- Zyprexa and Task Engagement in SchizophreniaPivotal-lookingWithdrawn
VA Connecticut Healthcare SystemFederal agency
NCT00440843 · 0 participants · Start Feb 2007 · Primary completion Jun 2012
Drug: Olanzapine (Zyprexa); Typicals · For: Schizophrenia; Schizoaffective Disorder
Sites: New York, New York
Alkermes, Inc.Industry
NCT07744113
Drug: OLZ/SAM · For: Bipolar 1 Disorder; Schizophrenia Disorder
Sites: Miami, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Biosynthesis of vanillin glucoside in Escherichia coli.
Tian M, Li J, Du Y, et al. · Synth Syst Biotechnol 2027
- Aptamer-enabled surface-imprinted self-assembled monolayer for glycoprotein detection based on the in situ self-assembly of lectin and glucose oxidase for signal amplification.
Xia N, Liu G, Zhang S, et al. · Talanta 2027
- PI-AttnGAN: Physics-informed attention generative modeling for cross-modal FT-IR-to-Raman serum spectral reconstruction.
Chang C, Lin J, Liu S, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
- Intrinsic dimension for evaluating and analyzing neural networks for medical image segmentation.
Li W, Li Z, Xu J, et al. · Comput Methods Programs Biomed 2027
- Molecular mechanisms underlying streptomycin resistance driven by gidB R96C and A133P in M. tuberculosis.
Song T, Li X, Yao J, et al. · Diagn Microbiol Infect Dis 2027
- From biomass side-product to nano-therapeutics: Characterization and anti-colitis efficacy of carbon dots originating from Nelumbinis Rhizomatis Nodus Carbonisatus.
Liang Y, Yu Z, Liu M, et al. · Colloids Surf B Biointerfaces 2027
Also in development for Bipolar I Disorder
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- LB-102Phase 34 trials
LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder
- ABBV-932Phase 23 trials
AbbVie · Bipolar I or II Disorder, Generalized Anxiety Disorder (GAD), Bipolar I Disorder
- AL-001lithium salicylate, L-proline cocrystalPhase 23 trials
Beijing Anlong Biopharmaceutical Co., Ltd. · Wet Age-related Macular Degeneration (wAMD), Bipolar I Disorder
- IcalcaprantABBV-1354, CVL-354Phase 22 trials
AbbVie · Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.